4.5 Article

Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms

期刊

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 87, 期 7, 页码 2777-2789

出版社

WILEY
DOI: 10.1111/bcp.14682

关键词

acute urinary retention; baseline risk factors; benign prostatic hyperplasia; disease-modifying properties; dutasteride; lower urinary tract symptoms; tamsulosin; time-to-event modelling

资金

  1. GlaxoSmithKline

向作者/读者索取更多资源

By analyzing pooled data, it was found that the use of dutasteride and tamsulosin-dutasteride combination therapy significantly reduced the baseline risk of acute urinary retention or BPH-related surgery. The study also highlighted the contribution of different baseline characteristics to the risk of these events, and emphasized that tamsulosin monotherapy has no impact on long-term risk for individuals.
Aims: Combination therapy of 5 alpha-reductase inhibitor and alpha-blocker is a guideline-endorsed therapeutic approach for patients with moderate-to-severe lower urinary tract symptoms or benign prostatic hyperplasia (LUTS/BPH) who are at risk of disease progression. We aimed to disentangle the contribution of clinical and demographic baseline characteristics affecting the risk of acute urinary retention or BPH-related surgery (AUR/S) from the effect of treatment with drugs showing symptomatic and disease-modifying properties. Methods: A time-to-event model was developed using pooled data from patients (n = 10 238) enrolled into six clinical studies receiving placebo, tamsulosin, dutasteride or tamsulosin-dutasteride combination therapy. A parametric hazard function was used to describe the time to first AUR/S. Covariate model building included the assessment of relevant clinical and demographic factors on baseline hazard. Predictive performance was evaluated by graphical and statistical methods. Results: An exponential hazard model best described the time to first AUR/S in this group of patients. Baseline International Prostate Symptom Score, prostate-specific antigen, prostate volume and maximum urine flow were identified as covariates with hazard ratio estimates of 1.04, 1.08, 1.01 and 0.91, respectively. Dutasteride monotherapy and tamsulosin-dutasteride combination therapy resulted in a significant reduction in the baseline hazard (56.8% and 66.4%, respectively). By contrast, the effect of tamsulosin did not differ from placebo. Conclusions: Our analysis showed the implications of disease-modifying properties of dutasteride and tamsulosin-dutasteride combination therapy for the risk of AUR/S. It also elucidated the contribution of different baseline characteristics to the risk of these events. The use of tamsulosin monotherapy (symptomatic treatment) has no impact on individual long-term risk.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据